These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36418428)

  • 41. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
    Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
    BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CMTM6 mediates the Warburg effect and promotes the liver metastasis of colorectal cancer.
    Shaha A; Wang Y; Wang X; Wang D; Guinovart D; Liu B; Kang N
    Exp Mol Med; 2024 Sep; 56(9):2002-2015. PubMed ID: 39218981
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.
    Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z
    Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
    Zhang C; Zhao S; Wang X
    Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells.
    Gohara Y; Tomonobu N; Kinoshita R; Futami J; Audebert L; Chen Y; Komalasari NLGY; Jiang F; Yoshizawa C; Murata H; Yamamoto KI; Watanabe M; Kumon H; Sakaguchi M
    J Mol Med (Berl); 2023 Apr; 101(4):431-447. PubMed ID: 36869893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
    Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
    BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
    Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
    Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.
    Koh YW; Han JH; Haam S; Jung J; Lee HW
    Oncoimmunology; 2019; 8(10):e1629261. PubMed ID: 31646074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.
    Sun X; Yan X; Zhuo W; Gu J; Zuo K; Liu W; Liang L; Gan Y; He G; Wan H; Gou X; Shi H; Hu J
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986511
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients.
    Li X; Chen L; Gu C; Sun Q; Li J
    PeerJ; 2020; 8():e9536. PubMed ID: 32874775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of BCLAF-1 in PD-L1 stabilization in response to ionizing irradiation.
    Ma Z; Wang H; Meng F; Han Y; Chen Y; Xiao M; Jiang H; Yu Z; Xu B
    Cancer Sci; 2021 Oct; 112(10):4064-4074. PubMed ID: 34251713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study.
    Huang X; Liu W; Liu C; Hu J; Wang B; Ren A; Huang X; Yuan Y; Liu J; Li M
    Front Mol Biosci; 2022; 9():983410. PubMed ID: 36589225
    [No Abstract]   [Full Text] [Related]  

  • 56. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.
    Chen L; Yang QC; Li YC; Yang LL; Liu JF; Li H; Xiao Y; Bu LL; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2020 Feb; 8(2):179-191. PubMed ID: 31771985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
    Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
    J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma.
    Wang Z; Peng Z; Liu Q; Guo Z; Menatola M; Su J; Li T; Ge Q; Wang P; Shen L; Jin R
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.